The role of kidney disease progression in heart failure prognosis: Bridging the evidence gap for optimal management
This article relates to:
-
Kidney status and events preceding death in heart failure: A real-world nationwide study
- Deewa Zahir Anjum,
- Caroline Hartwell Garred,
- Nicholas Carlson,
- Emil Fosbol,
- Mariam Elmegaard,
- Pardeep S. Jhund,
- John J.V. McMurray,
- Mark C. Petrie,
- Lars Kober,
- Morten Schou,
- Volume 27Issue 6European Journal of Heart Failure
- pages: 982-990
- First Published online: March 2, 2025
Riccardo M. Inciardi
ASST Spedali Civili of Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy
Search for more papers by this authorDaniel Steven
Heart Center, Department of Electrophysiology, University Hospital Cologne, Cologne, Germany
Search for more papers by this authorCorresponding Author
Gianluigi Savarese
Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden
Corresponding author. Department of Clinical Science and Education, Karolinska Institutet, Stockholm South General Hospital, Sjukhusbacken 10, 118 83 Stockholm, Sweden. Email: [email protected]
Search for more papers by this authorRiccardo M. Inciardi
ASST Spedali Civili of Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy
Search for more papers by this authorDaniel Steven
Heart Center, Department of Electrophysiology, University Hospital Cologne, Cologne, Germany
Search for more papers by this authorCorresponding Author
Gianluigi Savarese
Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden
Corresponding author. Department of Clinical Science and Education, Karolinska Institutet, Stockholm South General Hospital, Sjukhusbacken 10, 118 83 Stockholm, Sweden. Email: [email protected]
Search for more papers by this authorThe opinions expressed in this article are not necessarily those of the Editors of the European Journal of Heart Failure or of the European Society of Cardiology. doi: 10.1002/ejhf.3631.
References
- 1Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: A comprehensive and updated review of epidemiology. Cardiovasc Res 2023; 118: 3272–3287. https://doi.org/10.1093/cvr/cvac013
- 2Braunwald E. Diabetes, heart failure, and renal dysfunction: The vicious circles. Prog Cardiovasc Dis 2019; 62: 298–302. https://doi.org/10.1016/j.pcad.2019.07.003
- 3Vaduganathan M, Neuen BL, McCausland F, Jhund PS, Docherty KF, McMurray JJV, et al. Why has it been challenging to modify kidney disease progression in patients with heart failure? J Am Coll Cardiol 2024; 84: 2241–2245. https://doi.org/10.1016/j.jacc.2024.08.034
- 4Zahir Anjum D, Garred CH, Carlson N, Fosbol E, Elmegaard M, Jhund PS, et al. Kidney status and events preceding death in heart failure: A real-world nationwide study. Eur J Heart Fail 2025; 27: 982–990. https://doi.org/10.1002/ejhf.3631
- 5Filippatos G, Farmakis D, Parissis J. Renal dysfunction and heart failure: Things are seldom what they seem. Eur Heart J 2014; 35: 416–418. https://doi.org/10.1093/eurheartj/eht515
- 6Damman K, Valente MAE, Voors AA, O'Connor CM, Van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: An updated meta- analysis. Eur Heart J 2014; 35: 455–469. https://doi.org/10.1093/eurheartj/eht386
- 7Chatur S, Vaduganathan M, Claggett BL, Mc Causland FR, Desai AS, Jhund PS, et al. Dapagliflozin in patients with heart failure and deterioration in renal function. J Am Coll Cardiol 2023; 82: 1854–1863. https://doi.org/10.1016/j.jacc.2023.08.026
- 8Butt JH, McMurray JJV, Claggett BL, Jhund PS, Neuen BL, McCausland FR, et al. Therapeutic effects of heart failure medical therapies on standardized kidney outcomes: Comprehensive individual participant-level analysis of 6 randomized clinical trials. Circulation 2024; 150: 1858–1868. https://doi.org/10.1161/CIRCULATIONAHA.124.071110
- 9Cimino G, Vaduganathan M, Lombardi CM, Pagnesi M, Vizzardi E, Tomasoni D, et al. Obesity, heart failure with preserved ejection fraction, and the role of glucagon-like peptide-1 receptor agonists. ESC Heart Fail 2024; 11: 649–661. https://doi.org/10.1002/ehf2.14560
- 10Inciardi RM, Riccardi M, Savarese G, Metra M, Vaduganathan M, Solomon SD. Tailoring medical therapy for heart failure with preserved ejection fraction. Eur J Heart Fail 2025; 27: 190–193. https://doi.org/10.1002/ejhf.3558
- 11Inciardi RM, Chandra A, Pandey A, Metra M. Reframing the role of glucagon-like peptide 1 receptor agonists in cardiovascular medicine. ESC Heart Fail. https://doi.org/10.1002/ehf2.15123. Published online ahead of print 15/10/24.
- 12Mc Causland FR, Vaduganathan M, Claggett BL, Kulac IJ, Desai AS, Jhund PS, et al. Finerenone and kidney outcomes in patients with heart failure: The FINEARTS-HF trial. J Am Coll Cardiol 2025; 85: 159–168. https://doi.org/10.1016/j.jacc.2024.10.091
- 13Inciardi RM, Vaduganathan M, Lombardi CM, Gussago C, Agostoni P, Ameri P, et al.; OPTIPHARM-HF Investigators. OPTImal PHARMacological therapy for patients with heart failure: Rationale and design of the OPTIPHARM-HF registry. Eur J Heart Fail 2024; 26: 1707–1714. https://doi.org/10.1002/ejhf.3260
- 14Janse RJ, Fu EL, Dahlström U, Benson L, Lindholm B, van Diepen M, et al. Use of guideline-recommended medical therapy in patients with heart failure and chronic kidney disease: From physician's prescriptions to patient's dispensations, medication adherence and persistence. Eur J Heart Fail 2022; 24: 2185–2195. https://doi.org/10.1002/ejhf.2620
- 15Guidetti F, Lund LH, Benson L, Hage C, Musella F, Stolfo D, et al. Safety of continuing mineralocorticoid receptor antagonist treatment in patients with heart failure with reduced ejection fraction and severe kidney disease: Data from Swedish Heart Failure Registry. Eur J Heart Fail 2023; 25: 2164–2173. https://doi.org/10.1002/ejhf.3049
Citing Literature
